AngioDynamics Launches Sotradecol at American College of Phlebology Meeting.

QUEENSBURY, N.Y. -- Name of meeting in headline and first graph should read: American College of Phlebology (sted Phlebotomy).

The corrected release reads:

ANGIODYNAMICS LAUNCHES SOTRADECOL AT AMERICAN COLLEGE OF PHLEBOLOGY MEETING

AngioDynamics, Inc., (Nasdaq:ANGO) today announced it will launch Sotradecol(TM) at the 19th Annual Congress of the American College of Phlebology meeting to be held November 10-13, 2005 at the Hyatt Regency hotel in San Francisco, Calif. Sotradecol will be available for distribution in the United States after the ACP meeting.

AngioDynamics recently entered into an agreement with Bioniche Pharma Group Limited to distribute Sotradecol(TM), sodium tetradecyl sulfate, for the treatment of small, uncomplicated varicose veins. The agreement gives AngioDynamics exclusive rights to market and distribute Sotradecol to interventional radiologists, vascular surgeons and general surgeons in the United States. Sotradecol is the only FDA-approved, sodium tetradecyl sulfate injection in the United States.

Sotradecol has been shown to be an effective treatment of small uncomplicated varicose veins of the lower extremities. It is used in sclerotherapy, a non-surgical procedure to remove veins. An estimated 1.7 million patients undergo sclerotherapy each year in the U.S.

"We are very excited to feature Sotradecal at the upcoming ACP meeting," commented Eamonn P. Hobbs, president and CEO. "Now that Sotradecol is legally available for the treatment of smaller veins, we can provide greater treatment options to our customers, helping them to better serve their patients with varicose veins. In addition to our Venacure product line for the treatment of great saphenous vein insufficiency, we are now able to offer our customers a product geared toward the treatment of smaller veins, without the use of a laser."

David Doster, Product Manager for VenaCure products, remarked, "The health care industry has been waiting a long time for the approval of Sotradecol, as this well known drug provides another treatment option for patients who suffer from superficial venous disease. Sotradecol is now the only FDA-approved sodium tetradecyl sulfate available. Sotradecol is a great adjunct to our VenaCure product line and will significantly improve our position in the venous disease market by providing access to additional vein treatment centers and new vein treatment customers."

For additional information on Sotradecol, contact David Doster at 1-800-772-6446, ext. 126 or by email at [e-mail]. You may also visit the laser treatment web site at www.venacure.com.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, results of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.